Tiger Brokers

Nxera Pharma Unveils Corporate Presentation Highlighting Global Strategy and Drug Discovery Platform

Reuters
Feb 13
<a href="https://laohu8.com/S/SOLTF">Nxera Pharma</a> Unveils Corporate Presentation Highlighting Global <a href="https://laohu8.com/S/MSTR">Strategy</a> and Drug Discovery Platform

Nxera Pharma Co. Ltd. (TSE: 4565) has released a corporate presentation outlining its business overview, strategic roadmap, and financial results. The company reported JPY 19.5 billion or more in net product sales for FY2026, driven by its products PIVLAZ and QUVIVIQ. Commercial performance showed a 39% year-on-year revenue increase, with PIVLAZ sales up 7% and QUVIVIQ sales up 224%. Nxera Pharma also highlighted progress in its platform business, including multiple milestone receipts from partners such as Neurocrine, Centessa, Lilly, and AbbVie. The company has set objectives to acquire late-stage assets for Japan and the APAC region, sign high-value partnership deals, and initiate at least one partner-sponsored phase 2 trial. Cost reduction and achieving full-year profitability on an IFRS basis are also targeted. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on February 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10